To evaluate the Effect of Puerarin tablets versus statins in treating metabolism syndrome in patients with chronic rheumatic diseases
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
150
Approval No.: H19990258
270 Rongdu street, Jin-niu district,Rheumatology Center of Integrated Medicine, General Hospital of Chengdu Military Area Command PLA，
Chengdu, Sichuan, China
Change from baseline in homeostasis model assessment (HOMA-IR)
Time frame: At 0 week, 12 weeks, 24 weeks and 48 weeks
Fasting serum low-density lipoprotein cholesterol (LDL-C)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum high-density lipoprotein cholesterol (HDL-C)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
erythrocyte sedimentation rate (ESR)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
C reactive protein (CRP)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum total cholesterol (TC)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum triglycerides (TGs)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
tumor necrosis factor (TNFα)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-8 (IL-8)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-1 (IL-1)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-6 (IL-6)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Fasting serum insulin
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum glucose
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Kidney function
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Liver function
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
blood cell count
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks